Flunarizine, a clinically licensed diphenylmethylpiperazine and T-type calcium channel inhibitor prevents Hepatitis C virus membrane fusion in a genotype-dependent manner

P099 Flunarizine, a clinically licensed diphenylmethylpiperazine and T-type calcium channel inhibitor prevents Hepatitis C virus membrane fusion in a genotype-dependent manner PMS Perin, S Haid, RJP Brown, J Doerrbecker, K Schulze, C Zeilinger, M von Schaewen, B Heller, K Vercauteren, E Luxenburger, YM Baktash, FWR Vondran, A Kirschning, R M€ uller, CA Guzman, L Kaderali, G Randall, P Meuleman, A Ploss and T Pietschmann TWINCORE, Zentrum f€ur Experimentelle und Klinische Infektionsforschung GmbH, Hannover, Germany, Helmholtz Centre for Infection Research, Braunschweig, Germany, Leibniz Universit€at, Hannover, Germany, Princeton University, Princeton, NJ, USA, Ghent University, Ghent, Belgium, Helmholtz Institute for Pharmaceutical Research, Saarbr€ ucken, Germany, The University of Chicago, Chicago, IL, USA, Medizinische Hochschule Hannover, Hannover, Germany, Deutsches Zentrum f€ ur Infektionsforschung, Hannover, Germany, Helmholtz Centre of Infection Research, Braunschweig, Germany, Technische Universität Dresden, Dresden, Germany